Qiandao Fund
乾道基金
Qiandao Fund (乾道基金) is a Chinese venture capital firm active in hard-tech and healthcare investing, though elsewhere's corpus does not offer a detailed profile of its founding, scale, or strategy. What the record shows are its deal participations: it co-invested in Yuntu Semiconductor's Series B1 in late 2023 alongside BlueRun Ventures and others , returned for the company's B2 round in early 2024 , led the Series A of Yunchu New Energy in May 2024 with Zhenghai Group as co-investor , and followed on in Hygea Medical Technology's 2023 round led by Gaorong Ventures . Its pattern runs toward semiconductor, digital energy, and medical technology — sectors typical of RMB-denominated institutional funds backing domestic industrial upgrading.
AI-generated — may contain errors, please verify.
Coverage
BlueRun Ventures | Cloud Storage New Energy Closes Tens of Millions of RMB in Series A Funding to Build Digital Energy Computing System
Pioneered dynamic reconfigurable battery network technology
BlueRun Ventures | Yuntu Semiconductor Closes Hundreds of Millions of RMB in B2 Round
Paths to High-Quality, Commercially Viable Development of Domestic Chips
Yuntu Semiconductor Closes Hundreds of Millions of RMB in Series B1 Funding | BlueRun Ventures
The New Architect of China's Smart Vehicle Chip Development
Haijieya Completes New Funding Round to Build Integrated Platform for Interventional Oncology Treatment
Providing a comprehensive suite of minimally invasive interventional diagnosis and treatment solutions for oncology.
